Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Timber Pharmaceuticals, Inc. TMBR NYSE

NYSE • Healthcare • Biotechnology • US • USD

SharesGrow Score
19/100
0/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Timber Pharmaceuticals, Inc. (TMBR) — Analyst outlook / Analyst consensus target is. Based on 1 analyst ratings, the consensus is neutral — 1 Hold.

TMBR Analyst Ratings

Hold
1
Ratings
1 Hold
Based on 1 analysts giving stock ratings to Timber Pharmaceuticals, Inc. in the past 3 months
Rating breakdown
Hold
1 100%
0%
Buy
0 analysts
100%
Hold
1 analysts
0%
Sell
0 analysts

People Also View

ENTX
ENTX
Entera Bio Ltd.
$1.18
+4.42%
 NTRB
NTRB
Nutriband Inc.
$4.08
+0.49%
 ALRN
ALRN
Aileron Therapeutics, Inc.
$2.11
+9.33%
 SABS
SABS
SAB Biotherapeutics, Inc.
$4.05
+4.92%
 SNTI
SNTI
Senti Biosciences, Inc.
$0.94
+0.73%
 ARTL
ARTL
Artelo Biosciences, Inc.
$5.31
-1.85%
 TPST
TPST
Tempest Therapeutics, Inc.
$2.12
-5.57%
 CRIS
CRIS
Curis, Inc.
$0.66
+6.15%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message